ReviewDiagnostics (Basel, Switzerland)2022
The Urinary Microbiome: Role in Bladder Cancer and Treatment.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Schistosomiasis-Microbiota Interactions: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2024Pooled it
- Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.NPJ biofilms and microbiomes · 2026Article
- Neoadjuvant Intravesical Mitomycin C for NMIBC: A Phase III Single-Center, Open-Label Randomized Clinical Trial.Cancers · 2026Article
- Overview of tumor-resident intratumoral microbiota in human bladder cancer.Translational andrology and urology · 2026Article
- Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.Frontiers in oncology · 2026Review
- Mechanisms of microbiome-immune interactions in bladder cancer and targeted regulatory strategies.Frontiers in immunology · 2026Review
- The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.International journal of molecular sciences · 2025Review
- Gut microbiota and urological cancers: from microecological imbalance to potential for precision therapy.Discover oncology · 2025Review
- Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients.Cell death discovery · 2025Article
- The Role of the Microbiome in Cancer Therapies: Current Evidence and Future Directions.Hematology/oncology clinics of North America · 2025Review
- An Overview of the Association of the Urinary Tract Microbiome with Various Diseases and Implications for Therapeutics.Mini reviews in medicinal chemistry · 2025Review
- The infection-microbiome-immunity axis in bladder cancer: mechanistic insights and therapeutic perspectives.Frontiers in immunology · 2025Review
- Microbiome and bladder cancer: the role of probiotics in treatment.Future microbiology · 2025Review
- Squamous cell carcinoma of the urinary bladder in patients with chronic spinal cord injury: A case series.Spinal cord series and cases · 2024Article
- A review of urinary bladder microbiome in patients with bladder cancer and its implications in bladder pathogenesis.World journal of urology · 2024Review
- Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.Cancers · 2024Article
- Clostridium butyricum inhibits the inflammation in children with primary nephrotic syndrome by regulating Th17/Tregs balance via gut-kidney axis.BMC microbiology · 2024Article
- The Role of Metabolomics and Microbiology in Urinary Tract Infection.International journal of molecular sciences · 2024Review
- Update on the Effect of the Urinary Microbiome on Urolithiasis.Diagnostics (Basel, Switzerland) · 2023Review
- Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Commensal microbes have increasingly been found to be involved in the development and progression of cancer. The recent discovery of the urinary microbiome bolstered the notion that microbes might play a role in bladder cancer. Although microbial involvement in bladder neoplastic transformation and metastatic progression, except schisto somiasis, has not been established, accumulating research suggests that dysbiosis of the urinary microbiome can produce a chronically inflammatory urothelial microenvironment and lead to bladder cancer. In this review, we describe how the urinary microbiome might facilitate the development of bladder cancer by altering the host immune system and the kind of cytokines that are directly involved in these responses. We investigated the therapeutic possibilities of modulating the urinary microbiome, including immune checkpoint therapy. The responsiveness of patients to intravesical Bacillus Calmette-Guerin therapy was evaluated with respect to microbiome composition. We conclude by noting that the application of microbes to orchestrate the inflammatory response in the bladder may facilitate the development of treatments for bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.